At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Bevacizumab and Oxaliplatindrug
Likely dose
Bevacizumab and Oxaliplatin 85 mg/M2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Oxaliplatin for Neoplasms, Germ Cell and Embryonal. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Germ Cell and Embryonal
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedOct 2006
Primary CompletionOct 2012
Study CompletionNov 2014
TodayJul 2026
First PostedOct 30, 2006
Enrollment StartOct 1, 2006
Primary CompletionOct 1, 2012
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 19.7 years ago
Interventions
Bevacizumab and Oxaliplatindrug
Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes